Vireo Growth (VREOF) Retained Earnings (2020 - 2026)
Vireo Growth (VREOF) posted Retained Earnings of -$319.9 million for Q1 2026, down 6.78% sequentially from -$299.6 million in Q4 2025, and down 34.44% YoY from -$488.0 million in Q1 2025.
Vireo Growth (VREOF) Retained Earnings (2020 - 2026) Analysis & Trends
Vireo Growth has reported Retained Earnings for 7 years, with the latest figure at -$319.9 million in Q1 2026.
- Quarterly Retained Earnings fell 34.44% year-over-year to -$319.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$319.9 million (down 34.44% YoY) and the FY2025 annual result came in at -$299.6 million, down 29.45% from the prior year.
- Retained Earnings fell to -$319.9 million in Q1 2026 per VREOF's latest filing, from -$299.6 million in the prior quarter.
- Over five years, Retained Earnings peaked at -$150.0 million in Q1 2022 and troughed at -$319.9 million in Q1 2026.
- A 5-year average of -$217.0 million and a median of -$210.1 million in 2024 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2022 and 2024: Retained Earnings slumped 37.96% in 2022, then dropped 8.49% in 2024.
- Over 5 years, Retained Earnings stood at -$177.9 million in 2022, then decreased by 14.36% to -$203.4 million in 2023, then slipped by 13.77% to -$231.4 million in 2024, then decreased by 29.45% to -$299.6 million in 2025, then decreased by 6.78% to -$319.9 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$319.9 million, -$299.6 million, and -$279.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | 37.15 Bn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 28.26 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 14.65 Bn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 4.18 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 9.16 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 18.56 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 724.00 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 8.88 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 3.75 Bn |
| 10 | Vireo Growth | 487.39 Mn | 345.09 Mn | 95.30 Mn | -320.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -319.90 Mn |
| Dec 31, 2025 | -299.60 Mn |
| Sep 30, 2025 | -279.18 Mn |
| Jun 30, 2025 | -252.88 Mn |
| Mar 31, 2025 | -237.94 Mn |
| Dec 31, 2024 | -231.44 Mn |
| Sep 30, 2024 | -215.73 Mn |
| Jun 30, 2024 | -210.81 Mn |
| Mar 31, 2024 | -210.14 Mn |
| Dec 31, 2023 | -203.43 Mn |
| Sep 30, 2023 | -198.85 Mn |
| Jun 30, 2023 | -193.62 Mn |
| Mar 31, 2023 | -186.29 Mn |
| Dec 31, 2022 | -177.88 Mn |
| Sep 30, 2022 | -164.60 Mn |
| Jun 30, 2022 | -156.17 Mn |
| Mar 31, 2022 | -149.99 Mn |
| Dec 31, 2021 | -135.42 Mn |
| Sep 30, 2021 | -120.44 Mn |
| Jun 30, 2021 | -114.20 Mn |